印度食品安全监管机构周三向雀巢印度、Zydus Wellness、雅培医疗等公司发出通知，称其涉及婴幼儿产品的宣传主张违反规定。
India's food safety regulator issued notices to Nestle India , Zydus Wellness , Abbott Healthcare and others on Wednesday over promotional claims involving products for infants and children that it said breached rules.
雀巢印度、Zydus Wellness和雅培医疗在正常工作时间之外未立即回应置评请求。
Nestle India, Zydus Wellness and Abbott did not immediately respond to requests for comment outside regular business hours.
此举是在该监管机构提议禁止在6个月以内婴儿食品中添加蔗糖和果糖数日后采取的，随着印度加强食品安全监管并推行包装正面警示标签，这个超过1000亿美元的包装食品行业受到冲击。
The action comes days after the regulator proposed banning the addition of sucrose and fructose to foods for infants up to six months old, as India steps up scrutiny of food safety and pushes for front-of-pack warning labels, rattling the country's more than $100 billion packaged food industry.
印度食品安全标准局表示，发出通知涉及的产品包括Complan（康普兰）、Lactogen Pro 1 Powder（能恩Pro 1奶粉）、NAN Excella Pro Stage 1（超级能恩Pro 1段）和婴儿奶粉替代品。
The Food Safety and Standards Authority of India said it issued notices over products including Complan, Lactogen Pro 1 Powder, NAN Excella Pro Stage 1 and infant milk substitutes.
监管机构要求雀巢印度提供证据，支持其关于Lactogen Pro 1 Powder和NAN Excella Pro Stage 1婴儿配方奶粉具有消化和免疫系统益处的宣称。
The regulator asked Nestle India to provide evidence supporting claims about digestive and immune-system benefits for its Lactogen Pro 1 Powder and NAN Excella Pro Stage 1 infant formula products.
Zydus Wellness被要求为其Complan儿童饮料的宣传主张提供科学依据，包括标语“长得更高、更快。临床验证生长2倍”。印度食品安全标准局还就一条推广婴儿奶粉替代品的Instagram短视频，向社交媒体影响者Ira Fathima以及雅培医疗、雀巢印度等公司发出通知。
Zydus Wellness was asked to provide scientific justification for claims promoting its Complan children's drink, including the tagline "grow taller, faster. clinically proven 2X growth." FSSAI also issued notices to social media influencer Ira Fathima and companies including Abbott Healthcare and Nestle India over an Instagram reel promoting infant milk substitutes.